Zainab Adnan Hatem Alebady - University of AL-Qadisiyah, College of Pharmacy, Department of Laboratory and Clinical Science, Al-Diwaniyah city, Iraq
Oraas Adnan Hatem - University of AL-Qadisiyah, College of Science, Department of Chemistry, Al-Diwaniyah City, Iraq
Tabarak Abd AL-Hamza - University of AL-Qadisiyah, College of Pharmacy, Al-Diwaniyah City, Iraq
Fatima Mushtaq Sarhan - University of AL-Qadisiyah, College of Pharmacy, Al-Diwaniyah City, Iraq
Mohammed Mrauh Raham - University of AL-Qadisiyah, College of Pharmacy, Al-Diwaniyah City, Iraq

Hypertension has been linked to a higher risk of getting some malignancies and a higher cancer-related mortality rate. Furthermore, many anticancer medicines have been linked to developing new high blood pressure or deteriorating previously well-controlled hypertension. The P۵۳ tumor antigen is a mutation-hosting antigen. It is also one of the human tumors’ most common genetic changes. Tumor growth is thought to be produced by several stages of genetic damage, which can lead to a breakdown in cell cycle regulatory systems. The objective of this study was to investigate the relationship between high blood pressure and cancer development markers represented by p۵۳, the guardian of the genome, protein expression and its downstream regulator, p۲۱. ۲۰ hypertensive patients (۴۶-۷۰ years of age) were included in this study. Blood samples were collected from two study groups. ELISA Technique was used to detect the protein levels of P۵۳ and P۲۱. The data presented in this study indicate the effect of high blood pressure on cell cycle progression and suggest that programmed cell death is triggered by hypertension, which was reflected by the high expression of P۵۳ and its downstream regulator p۲۱. It is suggested by the data that high blood pressure could be considered a driving force in tumor development through indirect stimulation of cell proliferation to compensate the cell loss by apoptosis which can also drive the development of tumor cells.

Hypertension, p۵۳, p۲۱, Apoptosis, Antihypertensive drugs